Dr. Atanasio Pandiella Alonso :: Centro de investigación del Cáncer

NCBI-PubMed Articles

Publications

(*) Means equal contribution as senior authors.

2021

In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer.

Rojas K, Baliu-Piqué M, Manzano A, Saiz-Ladera C, García-Barberán V, Cimas FJ, Pérez-Segura P, Pandiella A, Győrffy B, Ocana A,
Cell Oncol (Dordr); 2021; ; 10.1007/s13402-020-0; 33469836

2020

What about incorporating selenium in the therapeutic regimen of SARS-CoV-2?

Benarba B, Pandiella A,
EXCLI J; 2020; 19(); 1544-1546; 33343271

Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.

Nieto-Jimenez C, Alcaraz-Sanabria A, Martinez-Canales S, Corrales-Sanchez V, Montero JC, Burgos M, Nuncia-Cantarero M, Pandiella A, Galan-Moya EM, Ocaña A,
Int J Mol Sci; 2020; 21(23); E9034; 33261142

Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine.

Fuentes-Antrás J, Guevara-Hoyer K, Baliu-Piqué M, García-Saenz JA, Pérez-Segura P, Pandiella A, Ocaña A,
Front Oncol; 2020; 10(); 605633; 33194771

Breast Cancer Heterogeneity and Response to Novel Therapeutics.

Baliu-Piqué M, Pandiella A, Ocana A,
Cancers (Basel); 2020; 12(11); E3271; 33167363

Proteolysis targeting chimeras (PROTACs) in cancer therapy.

Ocaña A, Pandiella A,
J Exp Clin Cancer Res; 2020; 39(1); 189; 32933565

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy.

Juan A, Cimas FJ, Bravo I, Pandiella A, Ocaña A, Alonso-Moreno C,
Pharmaceutics; 2020; 12(9); E802; 32854255

Medicinal Plants as Sources of Active Molecules Against COVID-19.

Benarba B, Pandiella A,
Front Pharmacol; 2020; 11(); 1189; 32848790

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment.

Juan A, Cimas FJ, Bravo I, Pandiella A, Ocaña A, Alonso-Moreno C,
Int J Mol Sci; 2020; 21(17); E6018; 32825618

PDCD4 limits prooncogenic neuregulin-ErbB signaling.

Montero JC, Pandiella A,
Cell Mol Life Sci; 2020; ; 10.1007/s00018-020-0; 32804243

Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1.

Cimas FJ, Manzano A, Baliu-Piqué M, García-Gil E, Pérez-Segura P, Nagy Á, Pandiella A, Győrffy B, Ocana A,
Cancers (Basel); 2020; 12(8); E2243; 32796628

Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.

Nieto-Jimenez C, Galan-Moya EM, Corrales-Sanchez V, Noblejas-Lopez MDM, Burgos M, Domingo B, Montero JC, Gomez-Juarez M, Picazo-Martinez MG, Esparís-Ogando A, Pandiella A, Ocaña A,
Cancer Lett; 2020; 491(); 50-59; 32735909

HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies.

Gandullo-Sánchez L, Capone E, Ocaña A, Iacobelli S, Sala G, Pandiella A,
EMBO Mol Med; 2020; 12(5); e11498; 32329582

Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis.

Desnoyers A, González C, Pérez-Segura P, Pandiella A, Amir E, Ocaña A,
Mol Diagn Ther; 2020; 24(2); 143-151; 32100239

Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.

García-Alonso S, Ocaña A, Pandiella A,
Trends Cancer; 2020; 6(2); 130-146; 32061303

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative

Corrales-Sanchez V, Noblejas-Lopez MDM, Nieto-Jimenez C, Pérez-Peña J, Montero JC, Burgos M, Galan-Moya EM, Pandiella A, Ocaña A,
J Cell Mol Med; 2020; 24(5); 3117-3127; 32032474

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.

Ocaña A, Amir E, Pandiella A,
Breast Cancer Res; 2020; 22(1); 15; 32005279

Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.

Ríos-Luci C, Díaz-Rodríguez E, Gandullo-Sánchez L, Díaz-Gil L, Ocaña A, Pandiella A,
Cancer Lett; 2020; 470(); 161-169; 31765734

2019

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors.

Alcaraz-Sanabria A, Baliu-Piqué M, Saiz-Ladera C, Rojas K, Manzano A, Marquina G, Casado A, Cimas FJ, Pérez-Segura P, Pandiella A, Győrffy B, Ocana A,
Front Oncol; 2019; 9(); 1486; 31998644

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.

Pérez-Pena J, Tibor Fekete J, Páez R, Baliu-Piqué M, García-Saenz JA, García-Barberán V, Manzano A, Pérez-Segura P, Esparís-Ogando A, Pandiella A, Győrffy B, Ocana A,
Front Immunol; 2019; 10(); 2802; 31921107

Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis.

Saleh RR, Peinado P, Fuentes-Antrás J, Pérez-Segura P, Pandiella A, Amir E, Ocaña A,
Front Oncol; 2019; 9(); 1040; 31681578

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.

Noblejas-Lopez MDM, Nieto-Jimenez C, Burgos M, Gomez-Juarez M, Montero JC, Esparís-Ogando A, Pandiella A, Galan-Moya EM, Ocaña A,
J Exp Clin Cancer Res; 2019; 38(1); 383; 31470872

Screening and Preliminary Biochemical and Biological Studies of [RuCl(-cymene)(,-bis(diphenylphosphino)-isopropylamine)][BF] in Breast Cancer Models.

Corrales Sánchez V, Nieto-Jimenez C, Castro-Osma JA, de Andrés F, Pacheco-Liñán PJ, Bravo I, Rodríguez Fariñas N, Niza E, Domínguez-Jurado E, Lara-Sánchez A, Ríos Á, Gómez Juárez M, Montero JC, Pandiella A, Shafir A, Alonso-Moreno C, Ocaña A,
ACS Omega; 2019; 4(8); 13005-13014; 31460427

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors.

Nieto C, Centa A, Rodríguez-Rodríguez JA, Pandiella A, Martín Del Valle EM,
Nanomaterials (Basel); 2019; 9(7); E948; 31261957

Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.

Saleh RR, Antrás JF, Peinado P, Pérez-Segura P, Pandiella A, Amir E, Ocaña A,
Cancer Treat Rev; 2019; 77(); 11-19; 31174180

Bryonia dioica aqueous extract induces apoptosis and G2/M cell cycle arrest in MDA‑MB 231 breast cancer cells.

Benarba B, Elmallah A, Pandiella A,
Mol Med Rep; 2019; 20(1); 73-80; 31115513

Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin.

Pérez-Peña J, Díaz-Rodríguez E, Sanz E, Pandiella A,
Nutrients; 2019; 11(5); E1068; 31091680

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

Morcillo-Garcia S, Noblejas-Lopez MDM, Nieto-Jimenez C, Pérez-Peña J, Nuncia-Cantarero M, Győrffy B, Amir E, Pandiella A, Galan-Moya EM, Ocana A,
PLoS One; 2019; 14(4); e0209134; 30990809

Mapping Bromodomains in breast cancer and association with clinical outcome.

Pérez-Pena J, Páez R, Nieto-Jimenez C, Sánchez VC, Galan-Moya EM, Pandiella A, Győrffy B, Ocana A,
Sci Rep; 2019; 9(1); 5734; 30952871

TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.

Díaz-Rodríguez E, Pérez-Peña J, Ríos-Luci C, Arribas J, Ocaña A, Pandiella A,
Cancer Lett; 2019; 453(); 34-44; 30928382

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICA

Ocana A, Gil-Martin M, Antolín S, Atienza M, Montaño Á, Ribelles N, Urruticoechea A, Falcón A, Pernas S, Orlando J, Montero JC, Escudero MJ, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A, Ruiz-Borrego M,
Breast Cancer Res Treat; 2019; 174(3); 693-701; 30607629

MEK5 promotes lung adenocarcinoma.

Sánchez-Fdez A, Ortiz-Ruiz MJ, Re-Louhau MF, Ramos I, Blanco-Múñez Ó, Ludeña D, Abad M, Sánchez-Martín M, Pandiella A, Esparís-Ogando A,
Eur Respir J; 2019; 53(2); 1801327; 30442718

2018

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tu

Noblejas-Lopez MDM, Morcillo-Garcia S, Nieto-Jimenez C, Nuncia-Cantarero M, Győrffy B, Galan-Moya EM, Pandiella A, Ocaña A,
PLoS One; 2018; 13(11); e0207776; 30485330

Refining Early Antitumoral Drug Development.

Ocaña A, García-Alonso S, Amir E, Pandiella A,
Trends Pharmacol Sci; 2018; 39(11); 922-925; 30279003

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Pérez-Peña J, Győrffy B, Amir E, Pandiella A, Ocaña A,
Breast Cancer Res Treat; 2018; 172(3); 725-732; 30206781

Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leuk

Guerra B, Martín-Rodríguez P, Díaz-Chico JC, McNaughton-Smith G, Jiménez-Alonso S, Hueso-Falcón I, Montero JC, Blanco R, León J, Rodríguez-González G, Estévez-Braun A, Pandiella A, Díaz-Chico BN, Fernández-Pérez L,
Oncotarget; 2018; 9(63); 32272; 30181817

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results.

Ocaña A, Amir E, Pandiella A,
Oncotarget; 2018; 9(61); 31915-31919; 30159132

Colorectal cancer and medicinal plants: Principle findings from recent studies.

Benarba B, Pandiella A,
Biomed Pharmacother; 2018; 107(); 408-423; 30099345

The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.

Centa A, Rodríguez-Barrueco R, Montero JC, Pandiella A,
Mol Oncol; 2018; 12(7); 1061-1076; 29683256

Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer.

Díaz-Rodríguez E, Sanz E, Pandiella A,
Int J Oncol; 2018; 53(1); 113-123; 29658597

Resistance to Antibody-Drug Conjugates.

García-Alonso S, Ocaña A, Pandiella A,
Cancer Res; 2018; 78(9); 2159-2165; 29653942

Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.

Martinez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B, Pandiella A, Galan-Moya EM, Ocaña A,
Cancer Med; 2018; 7(5); 1896-1907; 29575713

Transcriptome evolution from breast epithelial cells to basal-like tumors.

Santpere G, Alcaraz-Sanabria A, Corrales-Sanchez V, Pandiella A, Győrffy B, Ocaña A,
Oncotarget; 2018; 9(1); 453-463; 29416627

2017

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Pérez-Peña J, Corrales-Sanchez V, Amir E, Pandiella A, Ocana A,
Sci Rep; 2017; 7(1); 17530; 29235520

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing adva

Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, Trigo JM, Muñoz M, Pandiella A, Diego NG, Bezares S, Caballero R, Carrasco E, Urruticoechea A,
Oncotarget; 2017; 8(42); 73144-73153; 29069857

BET inhibitors as novel therapeutic agents in breast cancer.

Ocaña A, Nieto-Jimenez C, Pandiella A,
Oncotarget; 2017; 8(41); 71285-71291; 29050361

Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.

Orive-Ramos A, Seoane S, Ocaña A, Pandiella A, Montero JC,
Mol Oncol; 2017; 11(12); 1788-1805; 29032615

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.

Nieto-Jimenez C, Alcaraz-Sanabria A, Páez R, Pérez-Peña J, Corrales-Sanchez V, Pandiella A, Ocaña A,
Oncotarget; 2017; 8(38); 62834-62841; 28968952

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.

Alcaraz-Sanabria A, Nieto-Jimenez C, Corrales-Sanchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC, Burgos M, Llopis J, Galan-Moya EM, Pandiella A, Ocaña A,
Mol Cancer Ther; 2017; 16(11); 2552-2562; 28847989

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J,
Clin Cancer Res; 2017; 23(22); 7006-7019; 28821558

Neutrophils in cancer: prognostic role and therapeutic strategies.

Ocana A, Nieto-Jimenez C, Pandiella A, Templeton AJ,
Mol Cancer; 2017; 16(1); 137; 28810877

Antitumoral effect of Ocoxin in hepatocellular carcinoma.

Díaz-Rodríguez E, El-Mallah AM, Sanz E, Pandiella A,
Oncol Lett; 2017; 14(2); 1950-1958; 28781639

Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.

Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, Nadal-Serrano M, Arribas J, Ocaña A, Pandiella A,
Cancer Res; 2017; 77(17); 4639-4651; 28687619

Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.

Martinez-Canales S, Cifuentes F, López De Rodas Gregorio M, Serrano-Oviedo L, Galan-Moya EM, Amir E, Pandiella A, Győrffy B, Ocaña A,
PLoS One; 2017; 12(5); e0175128; 28472085

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jimenez C, Páez R, Corrales-Sanchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A,
Oncotarget; 2017; 8(13); 21733-21740; 28423514

Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs.

Tibau A, Díez-González L, Navarro B, Galan-Moya EM, Templeton AJ, Seruga B, Pandiella A, Amir E, Ocana A,
Mol Diagn Ther; 2017; 21(3); 337-343; 28247182

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.

Ocana A, Pandiella A,
Oncotarget; 2017; 8(13); 22218-22234; 28108739

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Nieto-Jimenez C, Alcaraz-Sanabria A, Pérez-Peña J, Corrales-Sanchez V, Serrano-Heras G, Galan-Moya EM, Serrano-Oviedo L, Montero JC, Burgos M, Llopis J, Pandiella A, Ocaña A,
Oncotarget; 2017; 8(12); 19478-19490; 28061448

ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA.

Talamillo A, Grande L, Ruiz-Ontañon P, Velasquez C, Mollinedo P, Torices S, Sanchez-Gomez P, Aznar A, Esparís-Ogando A, Lopez-Lopez C, Lafita C, Berciano MT, Montero JA, Vazquez-Barquero A, Segura V, Villagra NT, Pandiella A, Lafarga M, León J, Martínez-Climent JA, Sanz-Moreno V, Fernandez-Luna JL,
Oncogene; 2017; 36(12); 1733-174; 27641332

CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.

Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development.

Ocana A, Pandiella A,
Curr Cancer Drug Targets; 2017; 17(1); 48-52; 26648484

2016

Multisite phosphorylation of P-Rex1 by protein kinase C.

Montero JC, Seoane S, García-Alonso S, Pandiella A,
Oncotarget; 2016; 7(47); 77937-77949; 27788493

Antiproliferative Effect of Synadenium grantii Hook f. stems (Euphorbiaceae) and a Rare Phorbol Diterpene Ester.

Campos A, Vendramini-Costa DB, Longato GB, Zermiani T, Ruiz AL, de Carvalho JE, Pandiella A, Cechinel Filho V,
Int J Toxicol; 2016; 35(6); 666-671; 27466346

Targeting the EGF/HER Ligand-Receptor System in Cancer.

Esparís-Ogando A, Montero JC, Arribas J, Ocaña A, Pandiella A,
Curr. Pharm. Des.; 2016; 22(39); 5887-589; 27426127

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.

Pérez-Peña J, Serrano-Heras G, Montero JC, Corrales-Sanchez V, Pandiella A, Ocaña A,
Mol Cancer Ther; 2016; 15(8); 1823-33; 27256375

Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.

Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, Seruga B, Srikanthan A, Pandiella A, Amir E, Ocana A,
PLoS One; 2016; 11(5); e0154789; 27149669

Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.

Ocaña A, Díez-González L, Esparís-Ogando A, Montero JC, Amir E, Pandiella A,
Oncotarget; 2016; 7(29); 45042-45; 27074567

In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.

Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, Sánchez-Corrales V, Nieto-Jimenez C, Templeton AJ, Seruga B, Pandiella A, Amir E,
Oncotarget; 2016; 7(16); 22865-72; 26992217

Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer.

Ocaña A, Pérez-Peña J, Díez-González L, Sánchez-Corrales V, Templeton A, Seruga B, Amir E, Pandiella A,
Breast Cancer Res Treat; 2016; 156(1); 1-8; 26897635

Antitumoral effect of Ocoxin on acute myeloid leukemia.

Díaz-Rodríguez E, Hernandez-Garcia S, Sanz E, Pandiella A,
Oncotarget; 2016; 7(5); 6231-42; 26756220

Circulating DNA and Survival in Solid Tumors.

Ocaña A, Díez-González L, García-Olmo DC, Templeton AJ, Vera-Badillo F, José Escribano M, Serrano-Heras G, Corrales-Sanchez V, Seruga B, Andrés-Pretel F, Pandiella A, Amir E,
Cancer Epidemiol Biomarke; 2016; 25(2); 399-406; 26604269

Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node.

Seoane S, Montero JC, Ocaña A, Pandiella A,
Oncogene; 2016; 35(21); 2756-65; 26364598

Modulation of cereblon levels by anti-myeloma agents.

Díaz-Rodríguez E, Pandiella A,
Leuk Lymphoma; 2016; 57(1); 167-76; 25860244

2015

Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.

Ocana A, Ethier JL, Díez-González L, Corrales-Sanchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E,
Oncotarget; 2015; 6(37); 39538-49; 26446908

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.

Pandiella A, Morís F, Ocaña A, Núñez LE, Montero JC,
Oncotarget; 2015; 6(32); 32856-67; 26439989

Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors.

Serrano-Heras G, Cuenca-López MD, Montero JC, Corrales-Sanchez V, Morales JC, Núñez LE, Morís F, Pandiella A, Ocaña A,
Oncotarget; 2015; 6(31); 31272-83; 26418718

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.

Montero JC, García-Alonso S, Ocaña A, Pandiella A,
Oncotarget; 2015; 6(30); 30057-71; 26336133

Erratum: Achilles' heel of triple negative cancer.

Ocaña A, Montero JC, Pandiella A,
Oncoscience; 2015; 2(7); 659; 26328268

Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer.

Cuenca-López MD, Serrano-Heras G, Montero JC, Corrales-Sanchez V, Gomez-Juarez M, Gascón-Escribano MJ, Morales JC, Voisin V, Núñez LE, Morís F, Bader GD, Pandiella A, Ocaña A,
Oncotarget; 2015; 6(29); 27923-37; 26314846

Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer.

Hernandez-Garcia S, González V, Sanz E, Pandiella A,
Nutr Cancer; 2015; 67(7); 1159-69; 26241555

Tumor-infiltrating lymphocytes in breast cancer: ready for prime time?

Ocaña A, Díez-González L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E,
J Clin Oncol; 2015; 33(11); 1298-9; 25753437

The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma.

Rovida E, Di Maira G, Tusa I, Cannito S, Paternostro C, Navari N, Vivoli E, Deng X, Gray NS, Esparís-Ogando A, David E, Pandiella A, Dello Sbarba P, Parola M, Marra F,
Gut; 2015; 64(9); 1454-65; 25183205

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexametha

Ocio EM, Fernández-Lázaro D, San-Segundo L, López-Corral L, Corchete LA, Gutiérrez NC, Garayoa M, Paíno T, Garcia-Gomez A, Delgado M, Montero JC, Díaz-Rodríguez E, Mateos MV, Pandiella A, Couto S, Wang M, Bjorklund CC, San-Miguel JF,
Leukemia; 2015; 29(3); 705-14; 25102946

2014

Achilles' heel of triple negative cancer.

Ocaña A, Montero JC, Pandiella A,
Oncoscience; 2014; 1(12); 763-4; 25621292

Achilles' heel of triple negative cancer.

Ocaña A, Montero JC, Pandiella A,
Oncoscience; 2014; 1(2); 115-6; 25594005

The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorig

Iglesias JM, Leis O, Pérez Ruiz E, Gumuzio Barrie J, Garcia-Garcia F, Aduriz A, Beloqui I, Hernandez-Garcia S, Lopez-Mato MP, Dopazo J, Pandiella A, Menendez JA, Martin AG,
Front Oncol; 2014; 4(); 308; 25414831

Therapeutic potential of ERK5 targeting in triple negative breast cancer.

Ortiz-Ruiz MJ, Alvarez-Fernández S, Parrott T, Zaknoen S, Burrows FJ, Ocaña A, Pandiella A, Esparís-Ogando A,
Oncotarget; 2014; 5(22); 11308-18; 25350956

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progres

Garcia-Gomez A, De Las Rivas J, Ocio EM, Díaz-Rodríguez E, Montero JC, Martín M, Blanco JF, Sanchez-Guijo FM, Pandiella A, San Miguel JF, Garayoa M,
Oncotarget; 2014; 5(18); 8284-305; 25268740

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortes J, Baselga J, Perou CM, Prat A, Rubio IT, Arribas J,
J Natl Cancer Inst; 2014; 106(11); 10.1093/jnci/dju291; 25253614

Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis.

Templeton AJ, Díez-González L, Ace O, Vera-Badillo F, Seruga B, Jordan J, Amir E, Pandiella A, Ocaña A,
Cancer Treat Rev; 2014; 40(9); 1048-55; 25217796

NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.

Sánchez-Sánchez B, Gutiérrez-Herrero S, López-Ruano G, Prieto-Bermejo R, Romo-González M, Llanillo M, Pandiella A, Guerrero C, Miguel JF, Sánchez-Guijo F, Del Cañizo C, Hernández-Hernández A,
Clin. Cancer Res.; 2014; 20(15); 4014-25; 24833663

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.

Cuenca-López MD, Montero JC, Morales JC, Prat A, Pandiella A, Ocana A,
BMC Cancer; 2014; 14(); 302; 24779793

Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.

Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Díez-González L, Cuenca-López MD, Seruga B, Pandiella A, Amir E,
PLoS One; 2014; 9(4); e95219; 24777052

Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.

Chen X, Díaz-Rodríguez E, Ocio EM, Paiva B, Mortensen DS, Lopez-Girona A, Chopra R, Miguel JS, Pandiella A,
Mol Cancer Ther; 2014; 13(2); 504-16; 24431075

Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.

Ocaña A, Freedman O, Amir E, Seruga B, Pandiella A,
Cancer Metastasis Rev.; 2014; 33(1); 295-307; 24338003

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.

Montero JC, Esparís-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocaña A, Pandiella A,
Oncogene; 2014; 33(2); 148-56; 23246963

2013

Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.

Montero JC, Seoane S, Pandiella A,
Cell. Signal.; 2013; 25(11); 2281-9; 23899556

Molecular pathways: P-Rex in cancer.

Pandiella A, Montero JC,
Clin. Cancer Res.; 2013; 19(17); 4564-9; 23753921

ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Arias-González L, Moreno-Gimeno I, del Campo AR, Serrano-Oviedo L, Valero ML, Esparís-Ogando A, de la Cruz-Morcillo MA, Melgar-Rojas P, García-Cano J, Cimas FJ, Hidalgo MJ, Prado A, Callejas-Valera JL, Nam-Cha SH, Giménez-Bachs JM, Salinas-Sánchez AS, Pandiella A, del Peso L, Sánchez-Prieto R,
Neoplasia; 2013; 15(6); 649-59; 23730213

Scientific literature among smoking and respiratory system: repercussion and collaboration.

de Granda-Orive JI, Alonso-Arroyo A, García-Río F, Villanueva-Serrano S, Pandiella A, Aleixandre-Benavent R,
Arch. Bronconeumol.; 2013; 49(7); 282-8; 23562409

Potent antimyeloma activity of a novel ERK5/CDK inhibitor.

Alvarez-Fernández S, Ortiz-Ruiz MJ, Parrott T, Zaknoen S, Ocio EM, San Miguel J, Burrows FJ, Esparís-Ogando A, Pandiella A,
Clin. Cancer Res.; 2013; 19(10); 2677-87; 23532886

Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue.

Ruiz-Ontañon P, Orgaz JL, Aldaz B, Elosegui-Artola A, Martino J, Berciano MT, Montero JA, Grande L, Nogueira L, Diaz-Moralli S, Esparís-Ogando A, Vazquez-Barquero A, Lafarga M, Pandiella A, Cascante M, Segura V, Martínez-Climent JA, Sanz-Moreno V, Fernandez-Luna JL,
Stem Cells; 2013; 31(6); 1075-85; 23401361

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.

Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F,
Int. J. Cancer; 2013; 133(1); 235-46; 23292912

HER3 overexpression and survival in solid tumors: a meta-analysis.

Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E,
J. Natl. Cancer Inst.; 2013; 105(4); 266-73; 23221996

Targeting HER receptors in cancer.

Ocaña A, Pandiella A,
Curr. Pharm. Des.; 2013; 19(5); 808-17; 22973952

RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.

Garcia-Gomez A, Ocio EM, Pandiella A, San Miguel JF, Garayoa M,
Invest New Drugs; 2013; 31(1); 200-5; 22773056

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN,
Leukemia; 2013; 27(2); 430-40; 22763387

The evolving landscape of protein kinases in breast cancer: clinical implications.

Ocaña A, Amir E, Seruga B, Martín M, Pandiella A,
Cancer Treat. Rev.; 2013; 39(1); 68-76; 22703833

A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.

Morancho B, Parra-Palau JL, Ibrahim YH, Bernadó Morales C, Peg V, Bech-Serra JJ, Pandiella A, Canals F, Baselga J, Rubio I, Arribas J,
Oncogene; 2013; 32(11); 1452-9; 22641219

2012

Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.

Carrión-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, De Llorens R, Massaguer A,
Int. J. Oncol.; 2012; 41(3); 1128-38; 22684500

β-Lapachone analogs with enhanced antiproliferative activity.

Ríos-Luci C, Bonifazi EL, León LG, Montero JC, Burton G, Pandiella A, Misico RI, Padrón JM,
Eur J Med Chem; 2012; 53(); 264-74; 22560628

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.

Garcia-Gomez A, Ocio EM, Crusoe E, Santamaria C, Hernandez-Campo P, Blanco JF, Sanchez-Guijo FM, Hernández-Iglesias T, Briñón JG, Fisac-Herrero RM, Lee FY, Pandiella A, San Miguel JF, Garayoa M,
PLoS ONE; 2012; 7(4); e34914; 22539950

Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.

Montero JC, Chen X, Ocaña A, Pandiella A,
Mol. Cancer Ther.; 2012; 11(6); 1342-52; 22496482

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

Paiva B, Gutiérrez NC, Chen X, Vidriales MB, Montalbán MA, Rosiñol L, Oriol A, Martinez-Lopez J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Perez JJ, Fernandez-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martín A, Hernandez J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel JF, ,
Leukemia; 2012; 26(8); 1862-9; 22333880

CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.

Paíno T, Ocio EM, Paiva B, San-Segundo L, Garayoa M, Gutiérrez NC, Sarasquete ME, Pandiella A, Orfao A, San Miguel JF,
Haematologica; 2012; 97(7); 1110-4; 22315496

Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.

Sánchez-Martín M, Pandiella A,
Int. J. Cancer; 2012; 131(1); 244-52; 21826647

Sox2 expression in breast tumours and activation in breast cancer stem cells.

Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG,
Oncogene; 2012; 31(11); 1354-65; 21822303

2011

Deficient spindle assembly checkpoint in multiple myeloma.

Díaz-Rodríguez E, Alvarez-Fernández S, Chen X, Paiva B, López-Pérez R, García-Hernández JL, San Miguel JF, Pandiella A,
PLoS ONE; 2011; 6(11); e27583; 22132115

A modular approach to trim cellular targets in anticancer drug discovery.

Ríos-Luci C, Domínguez-Kelly R, León LG, Díaz-Rodríguez E, Freire R, Pandiella A, Cikotiene I, Padrón JM,
Bioorg. Med. Chem. Lett.; 2011; 21(22); 6641-5; 21986585

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

Montero JC, Seoane S, Ocaña A, Pandiella A,
Clin. Cancer Res.; 2011; 17(17); 5546-52; 21670084

Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.

Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, Ocaña A,
J. Clin. Oncol.; 2011; 29(18); 2543-9; 21606435

Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domains.

Montero JC, Rodríguez-Barrueco R, Pandiella A,
J. Biol. Chem.; 2011; 286(27); 24350-63; 21572038

Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

Colado E, Paíno T, Maiso P, Ocio EM, Chen X, Alvarez-Fernández S, Gutiérrez NC, Martín-Sánchez J, Flores-Montero J, San Segundo L, Garayoa M, Fernández-Lázaro D, Vidriales MB, Galmarini CM, Aviles P, Cuevas C, Pandiella A, San-Miguel JF,
Haematologica; 2011; 96(5); 687-95; 21330323

P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.

Montero JC, Seoane S, Ocaña A, Pandiella A,
Oncogene; 2011; 30(9); 1059-71; 21042280

Overexpression of HER2 signaling to WAVE2-Arp2/3 complex activates MMP-independent migration in breast cancer.

Yokotsuka M, Iwaya K, Saito T, Pandiella A, Tsuboi R, Kohno N, Matsubara O, Mukai K,
Breast Cancer Res. Treat.; 2011; 126(2); 311-8; 20419393

2010

Preclinical development of molecular-targeted agents for cancer.

Ocana A, Pandiella A, Siu LL, Tannock IF,
Nat Rev Clin Oncol; 2010; 8(4); 200-9; 21135887

Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.

Seoane S, Montero JC, Ocaña A, Pandiella A,
J. Natl. Cancer Inst.; 2010; 102(18); 1432-46; 20811002

Multisite phosphorylation of Erk5 in mitosis.

Díaz-Rodríguez E, Pandiella A,
J. Cell. Sci.; 2010; 123(Pt 18); 3146-56; 20736311

Personalized therapies in the cancer "omics" era.

Ocaña A, Pandiella A,
Mol. Cancer; 2010; 9(); 202; 20670437

Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis.

Palacios C, Martín-Pérez R, López-Pérez AI, Pandiella A, López-Rivas A,
Leuk. Res.; 2010; 34(11); 1533-8; 20667592

Do we have to change the way targeted drugs are developed?

Ocana A, Amir E, Seruga B, Pandiella A,
J. Clin. Oncol.; 2010; 28(24); e420-1; ; 20567014

Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival path

Redondo-Muñoz J, Escobar-Díaz E, Hernández Del Cerro M, Pandiella A, Terol MJ, García-Marco JA, García-Pardo A,
Clin. Cancer Res.; 2010; 16(17); 4382-91; 20534739

Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors.

León LG, Ríos-Luci C, Tejedor D, Pérez-Roth E, Montero JC, Pandiella A, García-Tellado F, Padrón JM,
J. Med. Chem.; 2010; 53(9); 3835-9; 20405921

Enhancement of antiproliferative activity by molecular simplification of catalpol.

García C, León LG, Pungitore CR, Ríos-Luci C, Daranas AH, Montero JC, Pandiella A, Tonn CE, Martín VS, Padrón JM,
Bioorg. Med. Chem.; 2010; 18(7); 2515-23; 20231098

[COPD. A model for using advanced directives and care planning].

Couceiro Vidal A, Pandiella A,
Arch. Bronconeumol.; 2010; 46(6); 325-31; 20097464

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multipl

Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernández-Lázaro D, Garayoa M, San-Segundo L, Hernández-Iglesias T, de Alava E, Shao W, Yao YM, Pandiella A, San-Miguel JF,
Haematologica; 2010; 95(5); 794-803; 19951978

2009

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.

Maiso P, Colado E, Ocio EM, Garayoa M, Martín J, Atadja P, Pandiella A, San-Miguel JF,
Leukemia; 2009; 23(12); 2265-74; 19812608

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R,
PLoS ONE; 2009; 4(7); e6124; 19568437

Novel tyrosine kinase inhibitors in the treatment of cancer.

Ocana A, Serrano R, Calero R, Pandiella A,
Curr Drug Targets; 2009; 10(6); 575-6; 19519359

Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.

Montero JC, Ocaña A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparís-Ogando A,
PLoS ONE; 2009; 4(5); e5565; 19440538

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors.

Garayoa M, García JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A, Hernández JM, Sanchez-Guijo FM, del Cañizo MC, Gutiérrez NC, San Miguel JF,
Leukemia; 2009; 23(8); 1515-27; 19357701

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-stran

Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernández S, San-Segundo L, Vilanova D, López-Corral L, Montero JC, Hernández-Iglesias T, de Alava E, Galmarini C, Aviles P, Cuevas C, San-Miguel JF, Pandiella A,
Blood; 2009; 113(16); 3781-91; 19020308

2008

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF,
Lancet Oncol; 2008; 9(12); 1157-65; 19038762

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J, Pandiella A,
Ann. Oncol.; 2008; 19(11); 1860-9; 18641009

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensi

Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL,
Mol Cell Biol; 2008; 28(18); 5605-20; 18625725

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.

Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC,
Cancer Res.; 2008; 68(13); 5216-25; 18593922

The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation.

Dorado F, Velasco S, Esparís-Ogando A, Pericacho M, Pandiella A, Silva J, López-Novoa JM, Rodríguez-Barbero A,
Nephrol. Dial. Transplant; 2008; 23(11); 3403-11; 18567890

Neuregulins and cancer.

Montero JC, Rodríguez-Barrueco R, Ocaña A, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A,
Clin. Cancer Res.; 2008; 14(11); 3237-41; 18519747

Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.

Montero JC, López-Pérez R, San Miguel JF, Pandiella A,
Haematologica; 2008; 93(6); 851-9; 18443272

The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.

Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, García-Echeverría C, Zimmermann J, Pandiella A, San Miguel JF,
Br J Haematol; 2008; 141(4); 470-82; 18341634

Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.

Ocaña A, Pandiella A,
Clin Cancer Res; 2008; 14(4); 961-70; 18281527

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.

Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF,
Haematologica; 2008; 93(1); 57-66; 18166786

2007

An update into the pathophysiological role of HER2 in cancer: therapeutic implications.

Ocaña A, Pandiella A,
Clin Transl Oncol; 2007; 9(9); 543-4; 17921099

Erk5 is activated and acts as a survival factor in mitosis.

Gírio A, Montero JC, Pandiella A, Chatterjee S,
Cell Signal; 2007; 19(9); 1964-72; 17624732

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.

de Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodriguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A,
J. Clin. Oncol.; 2007; 25(19); 2656-63; 17602072

Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis.

Borges J, Pandiella A, Esparís-Ogando A,
Cell. Signal.; 2007; 19(7); 1473-87; 17317102

Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis.

Ramirez JM, Ocio EM, San Miguel JF, Pandiella A,
Leukemia; 2007; 21(4); 797-804; 17315026

Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin.

Gómez-Benito M, Balsas P, Carvajal-Vergara X, Pandiella A, Anel A, Marzo I, Naval J,
Cell. Signal.; 2007; 19(4); 844-54; 17158029

The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.

Montero JC, Rodríguez-Barrueco R, Yuste L, Juanes PP, Borges J, Esparís-Ogando A, Pandiella A,
Mol. Biol. Cell; 2007; 18(2); 380-93; 17108327

Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.

Cruz JJ, Ocaña A, Del Barco E, Pandiella A,
Ann. Oncol.; 2007; 18(3); 421-30; 16873430

2006

ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo.

Garaude J, Cherni S, Kaminski S, Delepine E, Chable-Bessia C, Benkirane M, Borges J, Pandiella A, Iñiguez MA, Fresno M, Hipskind RA, Villalba M,
J. Immunol.; 2006; 177(11); 7607-17; 17114430

Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation.

Rodríguez-Barbero A, Obreo J, Alvarez-Munoz P, Pandiella A, Bernabeu C, López-Novoa JM,
Cell. Physiol. Biochem.; 2006; 18(1-3); 135-42; 16914898

TGF-beta1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells.

Rodríguez-Barbero A, Dorado F, Velasco S, Pandiella A, Banas B, López-Novoa JM,
Kidney Int.; 2006; 70(5); 901-9; 16820791

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A, San Miguel JF,
Cancer Res.; 2006; 66(11); 5781-9; 16740717

Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.

Ocaña A, Cruz JJ, Pandiella A,
Am. J. Clin. Oncol.; 2006; 29(1); 90-5; 16462510

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.

Blanco B, Perez-Simon JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, Lopez-Holgado N, Maiso P, Alberca M, Villaron E, Schenkein D, Pandiella A, San Miguel J,
Blood; 2006; 107(9); 3575-83; 16282346

Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes.

Parmo-Cabañas M, Molina-Ortiz I, Matías-Román S, García-Bernal D, Carvajal-Vergara X, Valle I, Pandiella A, Arroyo AG, Teixidó J,
J. Pathol.; 2006; 208(1); 108-18; 16278822

2005

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.

Yuste L, Montero JC, Esparís-Ogando A, Pandiella A,
Cancer Res.; 2005; 65(15); 6801-10; 16061662

Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells.

Yuste L, Esparís-Ogando A, Santos E, Pandiella A,
J. Biochem.; 2005; 137(6); 731-9; 16002995

Genetic abnormalities and patterns of antigenic expression in multiple myeloma.

Mateo G, Castellanos M, Rasillo A, Gutiérrez NC, Montalbán MA, Martín ML, Hernández JM, López-Berges MC, Montejano L, Bladé J, Mateos MV, Sureda A, de la Rubia J, Díaz-Mediavilla J, Pandiella A, Lahuerta JJ, Orfao A, San Miguel JF,
Clin. Cancer Res.; 2005; 11(10); 3661-7; 15897562

N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity.

Juanes PP, Ferreira L, Montero JC, Arribas J, Pandiella A,
Biochem. J.; 2005; 389(Pt 1); 161-72; 15777285

Multifunctional role of Erk5 in multiple myeloma.

Carvajal-Vergara X, Tabera S, Montero JC, Esparís-Ogando A, López-Pérez R, Mateo G, Gutiérrez N, Parmo-Cabañas M, Teixidó J, San Miguel JF, Pandiella A,
Blood; 2005; 105(11); 4492-9; 15692064

Bortezomib is an efficient agent in plasma cell leukemias.

Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, Schenkein D, Pandiella A, San Miguel JF,
Int. J. Cancer; 2005; 114(4); 665-7; 15609327

2004

Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultured L6E9 myoblasts.

Obreo J, Díez-Marques L, Lamas S, Düwell A, Eleno N, Bernabeu C, Pandiella A, López-Novoa JM, Rodríguez-Barbero A,
Cell Physiol Biochem; 2004; 14(4-6); 301-10; 15319534

A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines relea

Rodríguez-Caballero A, García-Montero AC, Bueno C, Almeida J, Varro R, Chen R, Pandiella A, Orfao A,
Lab Invest; 2004; 84(10); 1387-98; 15311213

2003

Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.

Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutiérrez N, San Miguel JF,
Br J Haematol; 2003; 123(5); 858-68; 14632777

Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding.

Borroto A, Ruiz-Paz S, de la Torre TV, Borrell-Pages M, Merlos-Suarez A, Pandiella A, Blobel CP, Baselga J, Arribas J,
J Biol Chem; 2003; 278(28); 25933-9; 12714588

2002

Mitogen-activated protein kinase routes as targets in the action of diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells.

Pipaón C, Gutierrez P, Montero JC, Lorenzo M, Eguiraun A, De la Fuente JA, Pandiella A, León J, Ortiz JM,
Mol Cancer Ther; 2002; 1(10); 811-9; 12492114

A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings.

Bueno C, Rodríguez-Caballero A, García-Montero A, Pandiella A, Almeida J, Orfao A,
J Immunol Methods; 2002; 264(1-2); 77-87; 12191512

Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated she

Díaz-Rodríguez E, Montero JC, Esparís-Ogando A, Yuste L, Pandiella A,
Mol. Biol. Cell; 2002; 13(6); 2031-44; 12058067

Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.

Montero JC, Yuste L, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A,
Biochem. J.; 2002; 363(Pt 2); 211-21; 11931648

Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E

Rodríguez-Barbero A, Obreo J, Yuste L, Montero JC, Rodríguez-Peña A, Pandiella A, Bernabeu C, López-Novoa JM,
FEBS Lett; 2002; 513(2-3); 282-8; 11904165

Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.

Esparís-Ogando A, Díaz-Rodríguez E, Montero JC, Yuste L, Crespo P, Pandiella A,
Mol. Cell. Biol.; 2002; 22(1); 270-85; 11739740

2000

Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme.

Montero JC, Yuste L, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A,
Mol. Cell. Neurosci.; 2000; 16(5); 631-48; 11083924

Stimulation of cleavage of membrane proteins by calmodulin inhibitors.

Díaz-Rodríguez E, Esparís-Ogando A, Montero JC, Yuste L, Pandiella A,
Biochem. J.; 2000; 346 Pt 2(); 359-67; 10677354

1999

Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.

Esparís-Ogando A, Díaz-Rodríguez E, Pandiella A,
Biochem. J.; 1999; 344 Pt 2(); 339-48; 10567214

Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms.

Díaz-Rodríguez E, Cabrera N, Esparís-Ogando A, Montero JC, Pandiella A,
Eur J Neurosci; 1999; 11(4); 1421-30; 10103137

1996

TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment.

Cabrera N, Díaz-Rodríguez E, Becker E, Martin-Zanca D, Pandiella A,
J Cell Biol; 1996; 132(3); 427-36; 8636219

Autocrine regulation of membrane transforming growth factor-alpha cleavage.

Baselga J, Mendelsohn J, Kim YM, Pandiella A,
J Biol Chem; 1996; 271(6); 3279-84; 8621731

1993

Oleic acid blocks epidermal growth factor-activated early intracellular signals without altering the ensuing mitogenic response.

Casabiell X, Zugaza JL, Pombo CM, Pandiella A, Casanueva FF,
Exp Cell Res; 1993; 205(2); 365-73; 8482341

Membrane-anchored growth factors.

Massagué J, Pandiella A,
Annu Rev Biochem; 1993; 62(); 515-41; 8394682

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.

Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Mendelsohn J,
J Natl Cancer Inst; 1993; 85(16); 1327-33; 8340945

Activated release of membrane-anchored TGF-alpha in the absence of cytosol.

Bosenberg MW, Pandiella A, Massagué J,
J Cell Biol; 1993; 122(1); 95-101; 8314849

1992

The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGF alpha into soluble growth factor.

Bosenberg MW, Pandiella A, Massagué J,
Cell; 1992; 71(7); 1157-65; 1473151

Cleavage of membrane-anchored growth factors involves distinct protease activities regulated through common mechanisms.

Pandiella A, Bosenberg MW, Huang EJ, Besmer P, Massagué J,
J Biol Chem; 1992; 267(33); 24028-33; 1385433

1991

Thyrotrophin-Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in viv

Spada A, Reza-Elahi F, Lania A, Pandiella A, Bassetti M, Bazzoni N, Alamo PG, Faglia G,
J Neuroendocrinol; 1991; 3(1); 51-6; 19215446

Multiple signals activate cleavage of the membrane transforming growth factor-alpha precursor.

Pandiella A, Massagué J,
J Biol Chem; 1991; 266(9); 5769-73; 2005114

Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process.

Pandiella A, Massagué J,
Proc Natl Acad Sci U S A; 1991; 88(5); 1726-30; 2000380

Regulation of epidermal-growth-factor-receptor signal transduction by cis-unsaturated fatty acids. Evidence for a protein kinase C-independent mechani

Casabiell X, Pandiella A, Casanueva FF,
Biochem J; 1991; 278 ( Pt 3; 679-87; 1898356

Transforming growth factor-alpha.

Pandiella A, Massagué J,
Biochem Soc Trans; 1991; 19(2); 259-62; 1889609

Transmembrane signalling at the epidermal growth factor receptor. Positive regulation by the C-terminal phosphotyrosine residues.

Magni M, Pandiella A, Helin K, Meldolesi J, Beguinot L,
Biochem J; 1991; 277 ( Pt 2; 305-11; 1713444

Ionic events induced by epidermal growth factor. Evidence that hyperpolarization and stimulated cation influx play a role in the stimulation of cell g

Magni M, Meldolesi J, Pandiella A,
J Biol Chem; 1991; 266(10); 6329-35; 1706715

1990

Voltage-operated calcium channels in small cell lung carcinoma cell lines: pharmacological, functional, and immunological properties.

Sher E, Pandiella A, Clementi F,
Cancer Res; 1990; 50(13); 3892-6; 2162247

1989

The effect of epidermal growth factor on membrane potential. Rapid hyperpolarization followed by persistent fluctuations.

Pandiella A, Magni M, Lovisolo D, Meldolesi J,
J Biol Chem; 1989; 264(22); 12914-21; 2787795

Plasma membrane hyperpolarization and [Ca2+]i increase induced by fibroblast growth factor in NIH-3T3 fibroblasts: resemblance to early signals genera

Pandiella A, Magni M, Meldolesi J,
Biochem Biophys Res Commu; 1989; 163(3); 1325-31; 2783138

Transmembrane signalling at the epidermal growth factor receptor.

Pandiella A, Beguinot L, Vicentini LM, Meldolesi J,
Trends Pharmacol Sci; 1989; 10(10); 411-4; 2694537

Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses.

Pandiella A, Lehvaslaiho H, Magni M, Alitalo K, Meldolesi J,
Oncogene; 1989; 4(11); 1299-305; 2573029

Voltage-operated calcium-channel subtypes in human neuroblastoma and rat pheochromocytoma cells.

Sher E, Pandiella A, Moresco RM, Clementi F,
Ann N Y Acad Sci; 1989; 560(); 249-50; 2545136

Reinforcement of signal generation at B2 bradykinin receptors by insulin, epidermal growth factors, and other growth factors.

Pandiella A, Meldolesi J,
J Biol Chem; 1989; 264(6); 3122-30; 2536735

1988

Generation of inositol phosphates, cytosolic Ca2+, and ionic fluxes in PC12 cells treated with bradykinin.

Fasolato C, Pandiella A, Meldolesi J, Pozzan T,
J Biol Chem; 1988; 263(33); 17350-9; 3141420

Alpha 1-adrenergic stimulation of in vitro growth hormone release and cytosolic free Ca2+ in rat somatotrophs.

Pandiella A, Elahi FR, Vallar L, Spada A,
Endocrinology; 1988; 122(4); 1419-25; 2894297

Second-messenger generation in PC12 cells. Interactions between cyclic AMP and Ca2+ signals.

Gatti G, Madeddu L, Pandiella A, Pozzan T, Meldolesi J,
Biochem J; 1988; 255(3); 753-60; 2850795

Transmembrane signalling at epidermal growth factor receptors overexpressed in NIH 3T3 cells. Phosphoinositide hydrolysis, cytosolic Ca2+ increase and

Pandiella A, Beguinot L, Velu TJ, Meldolesi J,
Biochem J; 1988; 254(1); 223-8; 2845945

Omega-conotoxin binding and effects on calcium channel function in human neuroblastoma and rat pheochromocytoma cell lines.

Sher E, Pandiella A, Clementi F,
FEBS Lett; 1988; 235(1-2); 178-82; 2456948

Intracellular calcium homeostasis in a human neuroblastoma cell line: modulation by depolarization, cholinergic receptors, and alpha-latrotoxin.

Sher E, Gotti C, Pandiella A, Madeddu L, Clementi F,
J Neurochem; 1988; 50(6); 1708-13; 2453611

1987

Protein kinase C-mediated feed back inhibition of the Ca2+ response at the EGF receptor.

Pandiella A, Vicentini LM, Meldolesi J,
Biochem Biophys Res Commu; 1987; 149(1); 145-51; 3500722

EGF raises cytosolic Ca2+ in A431 and Swiss 3T3 cells by a dual mechanism. Redistribution from intracellular stores and stimulated influx.

Pandiella A, Malgaroli A, Meldolesi J, Vicentini LM,
Exp Cell Res; 1987; 170(1); 175-85; 3494624

1986

Group

Ana Lucia Alcaraz Sanabria

Ana Lucia Alcaraz Sanabria

Telf.:

Fax:

Email: analucia_alcaraz@hotmail.com

Contact

Biography
×
Jorge Alejo

Jorge Alejo

Telf.:

Fax:

Email: jambasket_8@hotmail.com

Contact

Biography
×
Sheila Almaraz Postigo

Sheila Almaraz Postigo

Telf.:

Fax:

Email: sheilaalmaraz@gmail.com

Contact

Biography
×
Elisa Calvo Jiménez

Elisa Calvo Jiménez

Telf.:

Fax:

Email: elisacj_22@hotmail.com

Contact

Biography
×
Ariana Centa

Ariana Centa

Telf.:

Fax:

Email: ariana.aacc@hotmail.com

Contact

Biography
×
Laura Díaz Gil

Laura Díaz Gil

Telf.:

Fax:

Email: ldiazg@usal.es

Contact

Biography
×
María Elena Díaz Rodríguez

María Elena Díaz Rodríguez

Telf.:

Fax:

Email: ediaz@usal.es

Contact

Biography
×
Sabrina Fischer

Sabrina Fischer

Telf.:

Fax:

Email: sabrina.c.fischer@gmail.com

Contact

Biography
×
Adriana Patricia Freitas Matías

Adriana Patricia Freitas Matías

Telf.:

Fax:

Email: adrianamatias@ua.pt

Contact

Biography
×
Lucía Gandullo Sánchez

Lucía Gandullo Sánchez

Telf.:

Fax:

Email: lgandullo@usal.es

Contact

Biography
×
Sara García Alonso

Sara García Alonso

Telf.:

Fax:

Email: sara.garcia.alo@gmail.com

Contact

Biography
×
Mª Carmen Gómez García

Mª Carmen Gómez García

Telf.:

Fax:

Email: mamengomezgarcia@usal.es

Contact

Biography
×
Yolanda Mª Guillén Pérez

Yolanda Mª Guillén Pérez

Telf.:

Fax:

Email: u162364@usal.es

Contact

Biography
×
Basak Kurt

Basak Kurt

Telf.:

Fax:

Email: basakkurt.5@gmail.com

Contact

Biography
×
Claudriana Locatelli

Claudriana Locatelli

Telf.:

Fax:

Email: claudrilocatelli@gmail.com

Contact

Biography
×
Ana López Sánchez-Puga

Ana López Sánchez-Puga

Telf.:

Fax:

Email: ana.lopezsp@gmail.com

Contact

Biography
×
Neda Mansouri

Neda Mansouri

Telf.:

Fax:

Email: nedamansouri1983@gmail.com

Contact

Biography
×
Hong Marianne Wang

Hong Marianne Wang

Telf.:

Fax:

Email: h.m.wang@students.uu.nl

Contact

Biography
×
Sofia Matilla Vicente-Almazán

Sofia Matilla Vicente-Almazán

Telf.:

Fax:

Email: sofiamatilla@gmail.com

Contact

Biography
×
Juan Carlos Montero González

Juan Carlos Montero González

Telf.:

Fax:

Email: jcmon@usal.es

Contact

Biography
×
Paula Moreno Pomeda

Paula Moreno Pomeda

Telf.:

Fax:

Email: paula.cional@gmail.com

Contact

Biography
×
Cristina Nieto Jiménez

Cristina Nieto Jiménez

Telf.:

Fax:

Email: cnjimenez92@gmail.com

Contact

Biography
×
Alberto Ocaña Fernández

Alberto Ocaña Fernández

Telf.:

Fax:

Email: albertocana@yahoo.es

Contact

Biography
×
Chara Oikonomou

Chara Oikonomou

Telf.:

Fax:

Email: xaroula_-18@hotmail.com

Contact

Biography
×
Bouhniz Om Elez

Bouhniz Om Elez

Telf.:

Fax:

Email: omelez.ozza@gmail.com

Contact

Biography
×
Ana María Orive Ramos

Ana María Orive Ramos

Telf.:

Fax:

Email: ANANITA_OR@HOTMAIL.COM

Contact

Biography
×
Dr. Atanasio Pandiella Alonso

Dr. Atanasio Pandiella Alonso

ROLE OF SOLUBLE FACTORS AND MEMBRANE RECEPTORS IN PROCESSES OF PROLIFERATION, DIFFERENTIATION AND ONCOGENIC TRANSFORMATION

Telf.:

Fax:

Email: atanasio@usal.es

Contact

Dr. Atanasio Pandiella
Investigador científico del CSIC
Laboratorio Nº 15

923 294 815
923 294 743
atanasio(arroba)usal(.)es

Centro de Investigación del Cáncer (Universidad de Salamanca-CSIC)
Campus Universitario Miguel de Unamuno s/n
37007 Salamanca
SPAIN

Biography

Dr. Pandiella obtained his Ph.D degree in Medicine and Surgery from the University of Santiago de Compostela in 1987. His scientific training outside Spain includes four years (1985-1989) as a pre- and post-doctoral student at the Ospedale San Raffaele in Milan and three years at the Memorial Sloan Kettering Cancer Center (1989-1992 New York, U.S.A)
Later, for one year, Dr. Pandiella worked at the Department of Physiology of the University of Las Palmas in the Canary Islands. From 1994 up to 2001, he has been on the team of the Institute of Biochemical Microbiology of the University of Salamanca. His research line focuses on the functional characterisation of molecules involved in the genesis and promotion of different solid tumours in humans, in particular breast cancers.
×
Javier Pérez Peña

Javier Pérez Peña

Telf.:

Fax:

Email: javippv@gmail.com

Contact

Biography
×
Paulo Michel Pinheiro Ferreira

Paulo Michel Pinheiro Ferreira

Telf.:

Fax:

Email: pmpf@ufpi.edu.br

Contact

Biography
×
Mónica Redondo Puente

Mónica Redondo Puente

Telf.:

Fax:

Email: monicaredondo@usal.es

Contact

Biography
×
Carla Patricia Ríos Luci

Carla Patricia Ríos Luci

Telf.:

Fax:

Email: crluci@usal.es

Contact

Biography
×
Inés Romero Pérez

Inés Romero Pérez

Telf.:

Fax:

Email: romeroines1995@gmail.com

Contact

Biography
×
María José Ruiz Estrada

María José Ruiz Estrada

Telf.:

Fax:

Email: marruiest2@alum.us.es

Contact

Biography
×
Daniel Sánchez de Pedro

Daniel Sánchez de Pedro

Telf.:

Fax:

Email: dnsanchezdp@gmail.com

Contact

Biography
×
Laura Sánchez Díaz

Laura Sánchez Díaz

Telf.:

Fax:

Email: laura.sanchez.diaz@hotmail.com

Contact

Biography
×
Adrián Sánchez Fernández

Adrián Sánchez Fernández

Telf.:

Fax:

Email: adriansf@usal.es

Contact

Biography
×
Patricia Tomás Martín

Patricia Tomás Martín

Telf.:

Fax:

Email: patriciatm@usal.es

Contact

Biography
×
Maryam Torkaman

Maryam Torkaman

Telf.:

Fax:

Email: maryam.torkaman@usal.es

Contact

Biography
×
Alessandro Tubita

Alessandro Tubita

Telf.:

Fax:

Email: alessandro.tubita@student.unisi.it

Contact

Biography
×
Mary Luz Uribe

Mary Luz Uribe

Telf.:

Fax:

Email: mary.uribe@usal.es

Contact

Biography
×

Formers Members

Xi Chen

Xi Chen

Telf.:

Fax:

Email: biomed_cx@hotmail.com

Contact

Biography
×
Verónica Corrales Sánchez

Verónica Corrales Sánchez

Telf.:

Fax:

Email: Vero_nikac.s@hotmail.com

Contact

Biography
×
Virginia Fernández Chanca

Virginia Fernández Chanca

Telf.:

Fax:

Email: virginiaf@usal.es

Contact

Biography
×
Elaine Cristina Kormann

Elaine Cristina Kormann

Telf.:

Fax:

Email: mani_kormann@hotmail.com

Contact

Biography
×
Ana Paula Oliveira Hohne

Ana Paula Oliveira Hohne

Telf.:

Fax:

Email: anap.oliveira@gmail.com

Contact

Biography
×
Mª Florencia Re Louhau

Mª Florencia Re Louhau

Telf.:

Fax:

Email: mf_re@hotmail.com

Contact

Biography
×
María Dolores Rivero Megías

María Dolores Rivero Megías

Telf.:

Fax:

Email: lilly.934@hotmail.com

Contact

Biography
×
Fany Veronica Ticona Perez

Fany Veronica Ticona Perez

Telf.:

Fax:

Email: fanyveronica@gmail.com

Contact

Biography
×

Dr. Atanasio Pandiella Alonso

Biography

Contact

Areas of Research

Projects

Publications